Centre approved anti-viral medicines to treat COVID-19 patients, says SC

 thehindu.com  09/16/2020 12:47:30 

The Supreme Court on Wednesday said there was an approval by the Central government on use of Remdesivir and Fabiparivir as medicines to treat COVID-19.

The top court was hearing a plea seeking registration of an FIR by the CBI against ten Indian pharmaceutical firms for manufacturing and selling these two medicines for treating COVID-19 patients allegedly without valid licences.

Remdesivir and Favipiravir are antiviral drugs and their efficacy in treating COVID-19 patients have been a matter of debate among medical experts.

A bench comprising Chief Justice S.A. Bobde and Justices A.S. Bopanna and V. Ramasubramanian referred to the New Drugs and Clinical Trials Rules, 2018 and said these medicines have been permitted by the government for using in treatment of novel coronavirus patients.

You have not noticed this rule (New Drugs and Clinical Trials Rules) and filed this petition. We are adjourning this matter, you see the rules and then come back, the bench told lawyer M. Sharma who has filed the PIL.

Adjourning the hearing by two weeks, the bench said, There is approval by the Government of India for Remdesivir and Fabiparivir.

Seeking CBI probe, Mr. Sharma had filed the PIL alleging that these two medicines have been wrongly manufactured and sold for treating COVID-19 patients without any valid licences from the Central Drugs Standard Control Organisation.

That respondent no.3 to 10 are Indian pharmaceutical company who have signed partnership agreements with foreign companies that are Gilead Science Inc -U.S.A. and Fujifilm Japan, to manufacture and sale impugned drug, Remdesivir and Avagin (Favipiravir) in India. Without having a licence, the are manufacturing and selling impugned drugs as a medicine for corona in India, the PIL alleged.

Mr. Sharma has sought prosecution of the Indian companies for offences of cheating and criminal conspiracy besides under the provisions of the Drug Act, 1940.

The PIL said that these medicines have not been certified as medicines for Covid-19 till date by any country.

They are under trial and no country, including India, have issued licence to manufacture and sale them in the country..., it said.

The companies are manufacturing and selling them at very high rates in India and people are paying that due to the fear of COVID-19 infection and are dying, it said.

More than 300 doctors have died in hospitals where these two medicines have been supplied and it amounted to exploitation of public due to the fear of death.

Remdesivir was introduced by Gilead Science Inc. U.S.A. to treat Ebola Virus in Africa but it was not effective to treat Ebola virus as well, it said.

Favipiravir was developed by Fujifilm Toyama Chemical and was actually approved to treat Influenza .

The PIL has made the Ministry of Health and Family Welfare and the Central Drugs Standard Control Organisation as parties.

It has also made 10 pharmaceutical companies including Cipla Ltd, Dr. Reddys Laboratories Ltd, Hetero Labs Ltd and Zydus Cadila Healthcare Ltd as parties.

Stressing that there were no effective medicines for the pandemic, the plea said, the Prime Minister have already initiated process with Russia to import COVID-19 vaccine to manufacture/distribute in India through PSU Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL).

Dear reader,

We have been keeping you up-to-date with information on the developments in India and the world that have a bearing on our health and wellbeing, our lives and livelihoods, during these difficult times. To enable wide dissemination of news that is in public interest, we have increased the number of articles that can be read free, and extended free trial periods. However, we have a request for those who can afford to subscribe: please do. As we fight disinformation and misinformation, and keep apace with the happenings, we need to commit greater resources to news gathering operations. We promise to deliver quality journalism that stays away from vested interest and political propaganda.

Support Quality Journalism

Dear subscriber,

Thank you!

Your support for our journalism is invaluable. Its a support for truth and fairness in journalism. It has helped us keep apace with events and happenings.

The Hindu has always stood for journalism that is in the public interest. At this difficult time, it becomes even more important that we have access to information that has a bearing on our health and well-being, our lives, and livelihoods. As a subscriber, you are not only a beneficiary of our work but also its enabler.

We also reiterate here the promise that our team of reporters, copy editors, fact-checkers, designers, and photographers will deliver quality journalism that stays away from vested interest and political propaganda.

Suresh Nambath

« Go back